Shares of Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) reached a new 52-week low on Tuesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 25000 shares trading hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Price Performance
The firm has a market capitalization of C$663,150.00, a P/E ratio of -0.50 and a beta of -0.02. The company has a 50-day moving average price of C$0.01 and a 200-day moving average price of C$0.01. The company has a debt-to-equity ratio of 138.88, a quick ratio of 0.46 and a current ratio of 0.07.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Further Reading
- Five stocks we like better than Aequus Pharmaceuticals
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- What Investors Need to Know About Upcoming IPOs
- NVIDIA Insiders Sell: This Is What It Means for the Market
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
